Overview

Baricitinib is an oral, reversible inhibitor of the Janus kinase 1 and 2 (JAK1/JAK2) enzymes, used to modulate immune signalling in several chronic inflammatory conditions. The presentation addressed here is 4 mg film-coated tablets supplied in boxes of 60. For B2B buyers such as wholesalers, hospital pharmacies, and cross-border distributors, the priority is not the pharmacology alone but confirming a dependable, compliant supply chain before committing to volume. Its established regulatory history and oral administration make it a formulary staple across immunology and dermatology settings, which sustains steady wholesale demand.

Verifying Manufacturer and Registration

Before purchase, request the marketing authorisation or registration number valid in the destination market and confirm the manufacturing site holds current Good Manufacturing Practice certification. Because JAK inhibitors carry class-wide labelling about serious infections and thrombosis, importers should also verify that local regulatory status matches the intended indication and that the product insert is available in the required language. Reputable suppliers provide a Certificate of Analysis with each batch.

Storage and Cold-Chain Considerations

As an oral solid dosage form, baricitinib tablets do not require refrigerated transport, which simplifies logistics compared with biologics. They should be kept in closed primary packaging away from moisture and excessive heat, and cartons should remain sealed until dispensing. Distributors should still plan climate-controlled warehousing in hot climates to protect tablet integrity over long transit legs, and should monitor warehouse humidity. Sealed aluminium foils and desiccant inserts further protect each tablet from ambient moisture during extended shipping windows.

Batch Traceability and Shelf-Life Management

Procurement teams should insist on batch-level serialisation or at least batch numbers with expiry dates on every carton, enabling recall readiness and first-expired-first-out rotation. Because chronic therapies generate repeat demand, negotiate staggered delivery schedules that align with realistic sell-through rather than front-loading stock that risks expiry. Confirm the manufacturer's lead time and whether backup capacity exists to avoid disruption if a single line goes down.

FAQ

Q: Does baricitinib 4 mg require cold-chain shipping? A: No. As an oral tablet it is stable at controlled room temperature, though protection from moisture and heat during transit is still advisable.

Q: What documents should a distributor request per batch? A: At minimum a Certificate of Analysis, batch number with expiry, GMP evidence, and the relevant market registration or authorisation.

Q: How should shelf life be managed for repeat orders? A: Apply first-expired-first-out rotation and align delivery frequency with actual consumption to minimise the risk of expired stock.

Q: Is 4 mg the only strength relevant to sourcing? A: This listing is the 4 mg tablet in a 60-count box; confirm the strength and pack size match the prescriber demand in your target market.